Elenestinib

Phase 3

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Indolent Systemic Mastocytosis

Clinical Trial

Last updated: 12/4/2025

Developer

BPMC

Blueprint Medicines Corporation

Biotechnology•North America•NASDAQ

Related Pipeline

GIST

Solid Tumor, Unspecified, Child

Chronic Inducible Urticaria

Indolent Systemic Mastocytosis